AstraZeneca Announced Voydeya Approved In Canada As Add-on Therapy To Ravulizumab Or Eculizumab For Adults With PNH Who Have Residual Hemolytic Anemia Due To Extravascular Hemolysis
AstraZeneca Announced Voydeya Approved In Canada As Add-on Therapy To Ravulizumab Or Eculizumab For Adults With PNH Who Have Residual Hemolytic Anemia Due To Extravascular Hemolysis
Voydeya (danicopan tablets) has been approved in Canada as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor.2,3
Voydeya（danicopan片剂）已经在加拿大获得批准，作为补充到Ravulizumab或Eculizumab的治疗措施，治疗成人夜间发作性血红蛋白尿（PNH）患者的残留溶血性贫血，由于体外溶血（EVH）。1 Voydeya是首个口服的因子D抑制剂，作为标准标准板Ultomiris（Ravulizumab）或Soliris（Eculizumab）的补充，以满足在接受C5抑制剂治疗时经历临床意义的体外溶血（EVH）的约10 - 20％的PNH患者的需求。2,3